Klaudia has been working at Cellomatics as a Bioassay Scientist for two years, having joined the company after completing her PhD. She has always been interested in science from a young age and was particularly fascinated by biology and the sheer amount that is going on inside our body that most people are unaware of.
In our latest meet the team blog we discuss Klaudia’s experience at university and working for the NHS as well as the projects she has worked on during her time at Cellomatics.
Previous experience
Klaudia achieved an undergraduate degree in Biomedical Sciences at the University of Central Lancashire before going on to study her PhD at the same university. Her PhD focused on studying the effects of GSK3β inhibition in glioblastoma using novel compounds as well as the evaluation of their permeability through an in vitro blood brain barrier model.
During her time at university Klaudia also worked in an NHS Covid testing laboratory before moving on to work in the Point of Care and Rapid Testing team at her local hospital. Despite loving this work, Klaudia did not want to focus on the diagnostic side of the sciences forever and instead wanted to look for a company that focused on in vitro work and would also challenge and allow her to broaden her skillset as a scientist. This is where Cellomatics came in.
Projects at Cellomatics
Klaudia has always been fascinated by molecular biology and was pleased to be given the opportunity to expand her knowledge of molecular techniques such as siRNA transfection and qPCR at Cellomatics. She has enjoyed working across a large variety of projects within her two years at Cellomatics and is excited to begin working on more immunology-based projects.
Previously, Klaudia has been involved in projects including:
- A viral disinfection study where she carried out viral plaque assays to determine the efficacy of various disinfectants on different services
- Carrying out siRNA transfections on CRISPR knockout cell lines for validation of potential synthetic lethality gene pairs measured by qPCR, colony formation and cell viability assays
- Isolating B cells and testing client compounds on their ability to overcome the stimulation administered
Making a difference
Klaudia believes that improved in vitro disease modelling can drive the improvement of success rates in clinical testing. She is pleased to be working for a company that provides various in vitro testing platforms and drives further development in this area.
